Neuropsychiatry companies develop treatments, diagnostics and research technologies for conditions involving the interaction between brain function, behaviour and mental health. Their work spans psychiatric disorders, neurological symptoms and central nervous system drug discovery.
This category includes companies working on:
Browse 17 UK neuropsychiatry companies below.
Stem cell platform for precision psychiatry and drug discovery
MeOmics Precision Medicine is a biotechnology company developing a precision psychiatry platform that combines genomics, phenomics, and stem cell-based cellular assays to generate…
Small molecule neuromodulators for neuropsychiatric disorders
Draig Therapeutics is a clinical-stage biotech developing small molecule drugs that modulate the glutamate and GABA neurotransmitter pathways to treat neuropsychiatric disorders.…
Precision small molecule drugs for obsessive-compulsive disorder
Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct…
Clinical-stage therapeutics for oncology and behavioural brain disorders
TheraCryf is a clinical-stage drug development company developing small-molecule therapeutics for oncology and behavioural brain disorders. Its lead oncology candidate, derived…
AI-driven natural product discovery for neurological therapeutics
Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders. Its proprietary AI platform screens…